FY2027 Earnings Forecast for Immunovant, Inc. Issued By Truist Financial (NASDAQ:IMVT)

Immunovant, Inc. (NASDAQ:IMVT – Get Rating) – Research analysts at Truist Financial issued their FY2027 EPS estimates for shares of Immunovant in a report released on Tuesday, April 12th. Truist Financial analyst R. Karnauskas anticipates that the company will post earnings of $0.13 per share for the year. Truist Financial currently has a “Buy” rating and a $12.00 target price on the stock.

Immunovant (NASDAQ:IMVT – Get Rating) last released its quarterly earnings results on Friday, February 4th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02).

IMVT has been the subject of several other research reports. Chardan Capital reduced their price target on shares of Immunovant from $20.00 to $14.00 in a research report on Wednesday, March 30th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Immunovant in a research report on Monday, February 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Immunovant currently has a consensus rating of “Hold” and an average target price of $11.75.

IMVT stock opened at $5.00 on Thursday. The company has a fifty day moving average price of $5.53 and a 200 day moving average price of $7.15. Immunovant has a 12 month low of $4.76 and a 12 month high of $16.94. The company has a market cap of $581.98 million, a price-to-earnings ratio of -3.82 and a beta of 0.90.

In related news, CEO Peter Salzmann sold 19,227 shares of Immunovant stock in a transaction dated Thursday, March 24th. The stock was sold at an average price of $5.90, for a total value of $113,439.30. Following the transaction, the chief executive officer now owns 558,728 shares of the company’s stock, valued at approximately $3,296,495.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Julia G. Butchko sold 6,381 shares of Immunovant stock in a transaction dated Thursday, March 24th. The shares were sold at an average price of $5.90, for a total value of $37,647.90. Following the transaction, the insider now directly owns 283,107 shares in the company, valued at approximately $1,670,331.30. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Morgan Stanley raised its position in shares of Immunovant by 104.9% during the second quarter. Morgan Stanley now owns 1,542,372 shares of the company’s stock worth $16,303,000 after purchasing an additional 789,721 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in Immunovant by 400.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 106,532 shares of the company’s stock worth $1,126,000 after purchasing an additional 85,241 shares during the last quarter. Strs Ohio acquired a new position in Immunovant in the 3rd quarter valued at $71,000. SG Americas Securities LLC acquired a new position in Immunovant in the 3rd quarter valued at $241,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of Immunovant during the 3rd quarter worth $311,000. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Immunovant Company Profile (Get Rating)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.

Further Reading